BARD CR$100.09
+0.10
| Last Trade: |
100.09 |
| Trade Time: |
May 25 11:50 AM Eastern Daylight Time |
| Change: |
0.10 (0.10 %) |
| Prev Close: |
99.99 |
| Open: |
99.69 |
| Bid: |
100.07 |
| Ask: |
100.09 |
Quotes displayed are delayed by 15 minutes. Market data is provided by Telvent DTN
|
Date |
Name |
Title |
Volume |
Trade Price |
Holding Change |
|
5/11/2012
|
Alterio Sharon M
|
Group Vice President
|
10,585
|
$66.80
|
19.37%
|
|
5/11/2012
|
Alterio Sharon M
|
Group Vice President
|
-13,977
|
$101.21
|
-21.42%
|
|
5/9/2012
|
Lupisella Frank Jr
|
Vice President and Controller
|
-1,030
|
$100.71
|
-4.66%
|
|
5/9/2012
|
KELLY BRIAN P
|
Group Vice President
|
28,000
|
$66.80
|
60.17%
|
|
5/9/2012
|
KELLY BRIAN P
|
Group Vice President
|
-28,000
|
$100.63
|
-37.57%
|
Data provided by Insiderslab.com. To read detailed Insider Trading Research Report for (BCR), click here.
-
Covidien is looking to bridge its current valuation discount with a number of purer-play rivals.
Read More »
-
The biggest concern investors have with CareFusion is its low return on invested capital. Until it creates higher free cash flow, CareFusion is more than likely rangebound.
Read More »
-
C.R. Bard is posting modest operational growth but there is ample downside protection.
Read More »
-
Investors follow momentum trends because positive sentiment on a company can cause the momentum to persist.
Read More »
-
If you're looking for cutting-edge companies that have a chance to triple or quadruple in the coming months and years, don't look any further than today's best small biotechs, writes Mike Murphy of ...
Read More »
Free Reports
|
|
